147.84
-1.51 (-1.01%)
-1.51 (-1.01%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Seagen Inc | SGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -1.51 | -1.01% | 147.84 | 08:17:16 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 149.35 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 143.06 | 148.46 | 5.40 | - | - |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 18 | 402 | 973,136 | 90.57 - 213.94 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:00:32 | 13 | $ 150.00 | USD |
Seagen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 26.46B | 179.00M | 60.40M | $ 916.71M | $ 260.07M | -0.95 | 71.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Seagen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SGEN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 152.21 | 154.98 | 141.50 | 150.17 | 1,430,315 | -4.37 | -2.87% |
| 1 Month | 180.00 | 184.76 | 141.50 | 159.24 | 1,353,349 | -32.16 | -17.87% |
| 3 Months | 193.31 | 202.60 | 141.50 | 171.94 | 1,168,535 | -45.47 | -23.52% |
| 6 Months | 146.43 | 213.94 | 141.50 | 175.94 | 1,067,615 | 1.41 | 0.96% |
| 1 Year | 108.88 | 213.94 | 90.57 | 160.69 | 1,101,338 | 38.96 | 35.78% |
| 3 Years | 57.04 | 213.94 | 47.75 | 108.54 | 1,000,709 | 90.80 | 159.19% |
| 5 Years | 33.84 | 213.94 | 30.84 | 87.37 | 981,805 | 114.00 | 336.88% |
Seagen Description
| Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies. |
